Healthcare tech’s biggest busts

The Latest

• 

  One biotech’s approach to science-driven innovation

  Why some in the industry say fostering creativity in drug development is all about work structures.

  Biotech

• 

  Q&A // Biotech Spotlight

  Evommune’s unique method of drug discovery is more than skin deep

  The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

  Biotech

• 

  Avoiding a ‘bad trip’ in psychedelic clinical trials

  Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

  Biotech

• 

  The next era of Greater Boston’s biotech boom

  How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

  Biotech

• 

  Executive changes at Teva, Eversana could spell commercial growth in the new year

  With their latest personnel moves, these life sciences companies are preparing for major business shifts.

  Commercialization

• 

  Podcast

  Woman of the Week: Myriad Genetics’ Nicole Lambert

  Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

  Biotech

• 

  Profile

  How bacteria-enabled technology for wounds could also help cancer patients

  Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

  Biotech

• 

  Q&A

  In cancers with very low survival rates, Sellas aims higher

  The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

  Biotech

• 

  Why the biopharma ‘IPO playbook’ changed in 2022

  Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

  Biotech

• 

  Opinion

  Hybrid work is here to stay — here’s how leaders should adjust

  Executives across the life sciences share their tips for navigating the new norm of remote work.

  Leadership

• 

  4 pioneering social media campaigns in pharma this year

  The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate. 

  Commercialization

• 

  Is AI just hype or a real revolution in pharma? It’s complicated

  Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

  Biotech

• 

  To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

  A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

  Biotech

• 

  Podcast

  Woman of the Week: Janssen’s Najat Khan

  Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.

  Leadership

• 

  #HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

  Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

  Biotech

• 

  Profile

  A ‘bold vision’ to prevent diabetes

  Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

  Biotech

• 

  4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

  An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

  Biotech

• 

  Opinion

  Why the IRA will drive up the country’s drug bill — not lower it

  On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

  Biotech

• 

  Q&A

  The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

  Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

  Leadership

• 

  3 ways pharma can weather a recession

  If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

  Biotech

• 

  Q&A

  Novo Nordisk’s quantum bet on ‘world changing’ computing

  Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

  Biotech

• 

  Profile

  This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

  29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

  Biotech

• 

  Podcast

  Woman of the Week: 82VS’s Trier Bryant

  Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

  Biotech

• 

  Profile

  Chasing that ‘Time magazine cover potential’

  Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

  Biotech

• 

  While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

  Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

  Biotech